Ombline Ancelin
Simmons & Simmons
Simmons & Simmons
Client SatisfactionSimmons & Simmons continues to maintain its stellar reputation for pharma product liability disputes and arbitrations. The group handles a range of non-contentious mandates, including agreements between medical device manufacturers and healthcare institutions, and the registration of supplementary protection certificates (SPC). Alexandre Regniault leads the team alongside Jacques-Antoine Robert. Antoine-Robert is a specialist in biotech, and stands out due to his longstanding experience in handling large pharma product liability class actions. Regniault is noted for his deep regulatory knowledge, which he utilises to advise on the negotiation and drafting of clinical trial, licensing, and distribution agreements. Ombline Ancelin has a great deal of expertise in handling both contentious and non-contentious competition mandates within the life sciences space.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Very good expertise.’
‘This team establishes case law on pharmaceutical product liability. Very easy to contact, we feel the goodwill between them, and the sharing of skills.’
'The Simmons & Simmons team knows how to identify the key points of files and subjects on which we can mobilise. It is a team that is all the more responsive because it knows how to establish proximity in collaboration with the customer.'
Key clients
- Merck Santé
- Merck Serono
- Servier
- Carmat
- Rhythm Pharmaceuticals
- Bayer Healthcare
- Dana – Farber Cancer Institute
- Généthon
Work highlights
- Assisting Rhythm Pharmaceuticals in relation to the regulatory and data privacy aspects of their activities in Europe, both at EU level (incl. GDPR) and local laws.
- Assisting Bayer Healthcare within the framework of multi-jurisdictions claims lodged before civil (including two class actions) and administrative courts and before CCI in the context of various pharmaceutical products (a permanently implanted birth control medical device for women, a pharmaceutical products whose active ingredient is cyproterone acetate and oestroprogestative products).
- Assisting Généthon on strategic licensing projects and have, more specifically this year, assisted with the negotiation and drafting of a collaboration agreement with a Swedish listed company, to develop a pre-treatment to certain gene therapy for patients with anti-AAV antibodies.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Jacques-Antoine Robert
Simmons & SimmonsPractice head
The lawyer(s) leading their teams.
Alexandre Regniault, Jacques-Antoine Robert